Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
Delayed Quote. Delayed London Stock Exchange - 01/21 11:38:53 am
1644.6 GBX   +0.49%
08:01aNelson Peltz's Trian builds stake in Unilever - source
RE
01/21GSK, Vir ramping up U.S. output of COVID antibody drug
RE
01/21FTSE 100 Ends the Week Lower, Losing Year-to-Date Gains
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK names Pfizer scientist Dormitzer as vaccines R&D head

11/30/2021 | 08:00am EST

Nov 30 (Reuters) - GSK has hired one of the scientists behind Pfizer's mRNA COVID-19 shot, Phil Dormitzer, as its global head of R&D for vaccines and he will join the British drugmaker from Dec. 3, GSK said on Tuesday.

By poaching one of Pfizer's top vaccine scientists who played a pivotal role in developing its shot with BioNTech , GSK is strengthening its ranks after lagging in initial efforts to develop a coronavirus vaccine.

"The importance of vaccines has never been clearer, and the pace of technological innovation has rarely been greater ... Phil's scientific expertise and significant experience ... will be key to ensuring we remain a leader in this field," said Hal Barron, GSK chief scientific officer and R&D president.

Dormitzer's appointment is also a coup for Chief Executive Emma Walmsley as she defends GSK against activist shareholders. She has faced questions over her leadership and also of the scientific expertise at GSK as the company prepares to separate off its consumer health business.

GSK has so far focused on producing its adjuvant technology to boost the immune response of others' vaccines, and has teamed up with companies such as Vir and CureVac to develop treatments and improved mRNA vaccines.

Pfizer confirmed that Dormitzer was leaving the company.

"We are thankful to Phil for his deep contribution to Pfizer’s scientific efforts and his unwavering commitment to global health," the company said in a statement. (Reporting by Pushkala Aripaka in Bengaluru, Ludwig Burger in Frankfurt and Michael Erman in New York Editing by Keith Weir)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC 0.49% 1644.6 Delayed Quote.2.53%
VIR BIOTECHNOLOGY, INC. 0.97% 33.46 Delayed Quote.-20.09%
All news about GLAXOSMITHKLINE PLC
08:01aNelson Peltz's Trian builds stake in Unilever - source
RE
01/21GSK, Vir ramping up U.S. output of COVID antibody drug
RE
01/21FTSE 100 Ends the Week Lower, Losing Year-to-Date Gains
DJ
01/21Glaxo Unit Valuation Boost Looks Less Likely as Unilever Walks -- Market Insight
DJ
01/21Routine Vaccination Rates in Teens and Adults Continue to Lag Behind Pre-Pandemic Level..
BU
01/21Smith launches fresh attack on Unilever bosses
AQ
01/20Unilever Shareholder Calls for Improvement in Performance After Failed GSK-Pfizer Bid
MT
01/20ADRs Close Mostly Lower; Chinese Companies Traded Actively
DJ
01/20Global markets live: Unilever, United Airlines, Amazon, Walt Disney, Novavax...
01/20European ADRs Move Lower in Thursday Trading
MT
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Financials
Sales 2021 33 890 M 45 931 M 45 931 M
Net income 2021 4 080 M 5 529 M 5 529 M
Net Debt 2021 20 842 M 28 247 M 28 247 M
P/E ratio 2021 20,5x
Yield 2021 4,86%
Capitalization 82 884 M 112 B 112 B
EV / Sales 2021 3,06x
EV / Sales 2022 2,84x
Nbr of Employees 94 066
Free-Float -
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | MarketScreener
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 1 647,20 GBX
Average target price 1 748,83 GBX
Spread / Average Target 6,17%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC2.53%112 384
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356